Cargando…

Low-dose amikacin in the treatment of Multidrug-resistant Tuberculosis (MDR-TB)

BACKGROUND: The World Health Organization recommends intravenous amikacin for the treatment of MDR-TB at a dose of 15 mg/kg. However, higher doses are associated with significant toxicity. METHODS: Patients with MDR-TB treated at our institution receive amikacin at 8–10 mg/kg, with dose adjustment b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sabur, Natasha F., Brar, Mantaj S., Wu, Lisa, Brode, Sarah K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7945371/ https://www.ncbi.nlm.nih.gov/pubmed/33691624 http://dx.doi.org/10.1186/s12879-021-05947-6

Ejemplares similares

Predictors of Multidrug-Resistant Tuberculosis (MDR-TB) in Sudan
por: Ali, Monadil H., et al.
Publicado: (2019)

An Optimal Diagnostic Strategy for Tuberculosis in Hospitalized HIV-Infected Patients Using GeneXpert MTB/RIF and Alere Determine TB LAM Ag
por: Esmail, Aliasgar, et al.
Publicado: (2020)

Diagnosing tuberculosis in hospitalized HIV-infected individuals who cannot produce sputum: is urine lipoarabinomannan testing the answer?
por: Sabur, Natasha F., et al.
Publicado: (2017)

Molecular characterization of multidrug-resistant Mycobacterium tuberculosis (MDR-TB) isolates identifies local transmission of infection in Kuwait, a country with a low incidence of TB and MDR-TB
por: Al-Mutairi, Noura M., et al.
Publicado: (2019)

Clinical risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in Mali()
por: Baya, Bocar, et al.
Publicado: (2019)

Diagnostic Opportunities for Optimizing Management of Multidrug-Resistant Tuberculosis (MDR-TB) in Tanzania
por: Mpagama, Stellah G
Publicado: (2018)

Bedaquiline (BDQ) resistance in an adolescent with multidrug-resistant tuberculosis (MDR-TB): An alarm for pediatricians
por: Cesilia, Citra, et al.
Publicado: (2023)

Prevalence and Factors Associated with Multidrug-Resistant Tuberculosis (MDR-TB) among Presumptive MDR-TB Patients in Tigray Region, Northern Ethiopia
por: Mehari, Kibriti, et al.
Publicado: (2019)

Correction to: Molecular characterization of multidrug-resistant Mycobacterium tuberculosis (MDR-TB) isolates identifies local transmission of infection in Kuwait, a country with a low incidence of TB and MDR-TB
por: Al-Mutairi, Noura M., et al.
Publicado: (2020)

The Incidence of Amikacin Ototoxicity in Multidrug-ResistantTuberculosis Patients
por: Javadi, Mohammad Reza, et al.
Publicado: (2011)

Collaborative public–private initiatives targeting multidrug-resistant tuberculosis (MDR-TB) supported by the Lilly MDR-TB Partnership: experiences in 2012–2016
por: Shelby, Peter W, et al.
Publicado: (2017)

759. Molecular Characterization and Epidemiology of Multidrug-Resistant Mycobacterium tuberculosis (MDR-TB) and Identification of Possible Cases of Local Transmission of MDR-TB in Kuwait
por: Mokaddas, Eiman, et al.
Publicado: (2018)

Successful MDR-TB treatment regimens including Amikacin are associated with high rates of hearing loss
por: Modongo, Chawangwa, et al.
Publicado: (2014)

Linkage of Presumptive Multidrug Resistant Tuberculosis (MDR-TB) Patients to Diagnostic and Treatment Services in Cambodia
por: Khann, Sokhan, et al.
Publicado: (2013)

MDR-TB treatment as prevention: The projected population-level impact of expanded treatment for multidrug-resistant tuberculosis
por: Kendall, Emily A., et al.
Publicado: (2017)

Amikacin Concentrations Predictive of Ototoxicity in Multidrug-Resistant Tuberculosis Patients
por: Modongo, Chawangwa, et al.
Publicado: (2015)

Genome sequencing and annotation of multidrug resistant Mycobacterium tuberculosis (MDR-TB) PR10 strain
por: Halim, Mohd Zakihalani A., et al.
Publicado: (2016)

Evaluation of the frequency of mutation genes in multidrug-resistant tuberculosis (MDR-TB) strains in Beijing, China
por: Liu, Y., et al.
Publicado: (2021)

Alcohol use disorders in multidrug resistant tuberculosis (MDR-TB) patients and their non-tuberculosis family contacts in Nigeria
por: Lasebikan, Victor Olufolahan, et al.
Publicado: (2020)

Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada
por: Aznar, Maria Luisa, et al.
Publicado: (2019)

Factors associated with multidrug-resistant tuberculosis (MDR-TB) in Bhutan: A nationwide case-control study
por: Tenzin, Chador, et al.
Publicado: (2020)

A rare case of sarcoidosis with necrotizing mediastinal lymphadenitis misdiagnosed as multidrug-resistant tuberculosis (MDR- TB)
por: Prasad, Rajendra, et al.
Publicado: (2022)

Multidrug-Resistant TB (MDR-TB) and Extensively Drug-Resistant TB (XDR-TB) Among Children: Where We Stand Now
por: Chowdhury, Kona, et al.
Publicado: (2023)

High frequency of azole resistant Candida spp. colonization among presumptive multidrug resistant tuberculosis (MDR-TB) patients
por: Darma, Surya, et al.
Publicado: (2020)

Gridlock from Diagnosis to Treatment of Multidrug-Resistant Tuberculosis (MDR-TB) in Tanzania: Illuminating Potential Factors for Possible Intervention
por: Liyoyo, Alphonce A, et al.
Publicado: (2017)

Multidrug-resistant tuberculosis (MDR-TB) disease burden in China: a systematic review and spatio-temporal analysis
por: Ding, Peipei, et al.
Publicado: (2017)

Major depression and household food insecurity among individuals with multidrug-resistant tuberculosis (MDR-TB) in South Africa
por: Tomita, Andrew, et al.
Publicado: (2019)

Study of the prevalence of Multidrug-Resistant Pulmonary Tuberculosis (MDR-TB) in Western Rajasthan using line probe assay
por: Sharma, Mukesh, et al.
Publicado: (2020)

Sequential analysis as a tool for detection of amikacin ototoxicity in the treatment of multidrug-resistant tuberculosis
por: de Vasconcelos, Karla Anacleto, et al.
Publicado: (2018)

Artificial Intelligence and Amikacin Exposures Predictive of Outcomes in Multidrug-Resistant Tuberculosis Patients
por: Modongo, Chawangwa, et al.
Publicado: (2016)

The Correlations of Minimal Inhibitory Concentration Values of Anti-TB Drugs with Treatment Outcomes and Clinical Profiles in Patients with Multidrug-Resistant Tuberculosis (MDR-TB) in China
por: Tang, Qin, et al.
Publicado: (2022)

Patterns of Treatment Interruption among Patients with Multidrug-Resistant TB (MDR TB) and Association with Interim and Final Treatment Outcomes
por: Podewils, Laura Jean, et al.
Publicado: (2013)

Epidemiology of multidrug-resistant tuberculosis (MDR-TB) in Ethiopia: a systematic review and meta-analysis of the prevalence, determinants and treatment outcome
por: Girum, Tadele, et al.
Publicado: (2018)

Better programmatic outcome with the shorter regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Guinea: A retrospective cohort study
por: Hassane-Harouna, Souleymane, et al.
Publicado: (2020)

Comparison of characteristics and mortality in multidrug resistant (MDR) and non-MDR tuberculosis patients in China
por: Sun, Yanni, et al.
Publicado: (2015)

Bedaquiline Drug Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective In Vitro Surveillance Study of Bedaquiline and Other Second-Line Drug Susceptibility Testing in MDR-TB Isolates
por: Kaniga, Koné, et al.
Publicado: (2022)

‘Z(S)-MDR-TB' versus ‘Z(R)-MDR-TB': improving treatment of MDR-TB by identifying pyrazinamide susceptibility
por: Zhang, Ying, et al.
Publicado: (2012)

Gridlock from diagnosis to treatment of multidrug resistant tuberculosis (MDR-TB) in Tanzania: patients’ perspectives from a focus group discussion
por: Mpagama, Stellah G., et al.
Publicado: (2020)

Risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in a tertiary armed force referral and teaching hospital, Ethiopia
por: Demile, Biresaw, et al.
Publicado: (2018)

Assessment of drug-susceptible and multidrug-resistant tuberculosis (MDR-TB) in the Central Region of Somalia: A 3-year retrospective study
por: Mohamed, Mohamed Abdelrahman, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_113iq4e22b9bat52i4amugjilo